131 related articles for article (PubMed ID: 21810746)
1. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Takahashi A; Kubo M; Kamatani N; Chantratita W; Nakamura Y
Clin Infect Dis; 2011 Aug; 53(4):341-8. PubMed ID: 21810746
[TBL] [Abstract][Full Text] [Related]
2. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P
J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
[TBL] [Abstract][Full Text] [Related]
6. [Future direction of pharmacogenomics: identification of genes associated with risk of adverse drug reactions using genome-wide association study].
Mushiroda T
Rinsho Byori; 2014 Jan; 62(1):83-8. PubMed ID: 24724431
[TBL] [Abstract][Full Text] [Related]
7. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
[TBL] [Abstract][Full Text] [Related]
8. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
Kiertiburanakul S; Khongnorasat S; Rattanasiri S; Sungkanuparph S
J Med Assoc Thai; 2007 Feb; 90(2):237-43. PubMed ID: 17375626
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
[TBL] [Abstract][Full Text] [Related]
11. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
Launay O; Roudière L; Boukli N; Dupont B; Prévoteau du Clary F; Patey O; David F; Lortholary O; Devidas A; Piketty C; Rey E; Urbinelli R; Allaert FA; Tréluyer JM; Caumes E;
Clin Infect Dis; 2004 Apr; 38(8):e66-72. PubMed ID: 15095233
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
[TBL] [Abstract][Full Text] [Related]
13. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.
Wangsomboonsiri W; Mahasirimongkol S; Chantarangsu S; Kiertiburanakul S; Charoenyingwattana A; Komindr S; Thongnak C; Mushiroda T; Nakamura Y; Chantratita W; Sungkanuparph S
Clin Infect Dis; 2010 Feb; 50(4):597-604. PubMed ID: 20073992
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
15. Experience with nevirapine in previously treated HIV-1-infected individuals.
Wit FW;
Antivir Ther; 2000 Dec; 5(4):257-66. PubMed ID: 11142620
[TBL] [Abstract][Full Text] [Related]
16. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Saghayam S; Kumarasamy N; Cecelia AJ; Solomon S; Mayer K; Wanke C
Clin Infect Dis; 2007 Jan; 44(2):295-300. PubMed ID: 17173234
[TBL] [Abstract][Full Text] [Related]
17. Poor replication of candidate genes for major depressive disorder using genome-wide association data.
Bosker FJ; Hartman CA; Nolte IM; Prins BP; Terpstra P; Posthuma D; van Veen T; Willemsen G; DeRijk RH; de Geus EJ; Hoogendijk WJ; Sullivan PF; Penninx BW; Boomsma DI; Snieder H; Nolen WA
Mol Psychiatry; 2011 May; 16(5):516-32. PubMed ID: 20351714
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.
Shenton JM; Teranishi M; Abu-Asab MS; Yager JA; Uetrecht JP
Chem Res Toxicol; 2003 Sep; 16(9):1078-89. PubMed ID: 12971795
[TBL] [Abstract][Full Text] [Related]
19. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
